These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6839003)

  • 1. Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects.
    Osman MA; Patel RB; Irwin DS; Welling PG
    Biopharm Drug Dispos; 1983; 4(1):63-72. PubMed ID: 6839003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of four slow-release theophylline formulations in the beagle dog.
    Koritz GD; McKiernan BC; Neff-Davis CA; Munsiff IJ
    J Vet Pharmacol Ther; 1986 Sep; 9(3):293-302. PubMed ID: 3761420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability.
    Rivera-Calimlim L; Calimlim JF; Liang R; Lasagna L; Diamond GL
    J Asthma; 1986; 23(3):113-22. PubMed ID: 3528119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theophylline absorption from two sustained-release products. Implications for therapeutic drug monitoring.
    Rogers RJ; Wiener MB; Hill MR; Szefler SJ
    Am Rev Respir Dis; 1987 Nov; 136(5):1168-73. PubMed ID: 3674579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relation of product formulation to absorption of oral theophylline.
    Weinberger M; Hendeles L; Bighley L
    N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption of sustained-release theophylline tablets.
    Fagerström PO; Heintz L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans.
    Raz I; Bialer M; Salame K; Bar-On H
    Eur J Clin Pharmacol; 1984; 26(3):401-3. PubMed ID: 6734702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
    Hurwitz A; Karim A; Burns TS
    J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline.
    Brazier JL; Benchekroun Y; Gillet A; Andre C
    Eur J Clin Pharmacol; 1989; 37(1):85-90. PubMed ID: 2591470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of whole and half Theo-Dur tablets.
    Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():62-6. PubMed ID: 6934089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
    Weinberger MM
    Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption of theophylline from conventional and sustained-release tablets.
    Mellstrand T; Svedmyr N; Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
    Hussein Z; Friedman M
    Pharm Res; 1990 Nov; 7(11):1167-71. PubMed ID: 2293217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
    Hendeles L; Iafrate RP; Weinberger M
    Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of a new sustained-release theophylline capsule in fasted and non-fasted healthy subjects: single and multiple dosing studies.
    West RJ; Boehm G; Dwyer M; Williams DB; Sansom LN; Penna AC
    Biopharm Drug Dispos; 1990 Mar; 11(2):165-77. PubMed ID: 2328301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle.
    Karim A; Burns T; Wearley L; Streicher J; Palmer M
    Clin Pharmacol Ther; 1985 Jul; 38(1):77-83. PubMed ID: 4006379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food on bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms: Part I.
    Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I
    Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):148-52. PubMed ID: 3699941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.